+44 (0) 1698 534002
Contact

News

From Cybersecurity to Chemistry: Applying anomaly detection to expand a fragment collection

25 June 2025

In drug discovery, the quality and diversity of our screening libraries are paramount. In fragment-based drug discovery,...

Read more

Working with Asynt

25 June 2025

At BioAscent, we have invested over £3 million in R&D equipment since 2020, and our commitment to innovation and sus...

Read more

BioAscent expands compound library portfolio with chemogenomic set to accelerate drug discovery

21 May 2025

BioAscent is pleased to announce the acquisition of a high-value chemogenomic compound library which significantly enhan...

Read more

BioAscent Enhances Capabilities with New Flow Cytometer

09 May 2025

BioAscent is pleased to announce the recent investment in a new NovoCyte 3000 flow cytometer, a cutting-edge piece of eq...

Read more

BioAscent appoints James Hitchin as Vice President of Alliance Management

05 May 2025

BioAscent is pleased to announce the appointment of life sciences executive leader, James Hitchin, as Vice President of...

Read more

BioAscent invests in Seahorse XF Pro Analyser Platform

17 March 2025

BioAscent’s latest investment in a state-of-the-art Seahorse XF Pro Analyser Platform has strengthened the company’s mit...

Read more

BioAscent significantly outperforms market despite challenging market conditions

25 February 2025

“Green shoots” show signs of recovery in the sector, with BioAscent winning a number of new contracts.BioAscent has repo...

Read more

Meet the Team: Michael Mathieson, Senior Scientist - Chemistry

16 December 2024

In our latest Meet the Team blog, we asked Michael Mathieson about his career journey, from what inspired him to get int...

Read more

From placement to permanent: BioAscent welcomes Rita Pereira to the biosciences team

10 December 2024

BioAscent is pleased to welcome Rita Pereira back to the company as a permanent member of the biosciences team, followin...

Read more

BioAscent's leading expertise in GPCR drug discovery drives customer success

26 November 2024

We never set out to become a specialist GPCR drug discovery company, nor do we see ourselves as one today. Our identity...

Read more

Integrated Drug Discovery

Science-led drug discovery

Compound Management

Connecting and accelerating your drug discovery

Medicinal Chemistry

Proven expertise in design and synthesis

In Silico Discovery

Accelerating drug design with computational expertise

Discovery Biology

Screening expertise across target classes

Get in Touch

Let's talk about how we can maximise your drug discovery success.

Contact